- Home
- JKS vs XERS Comparison
JKS vs XERS Comparison
Compare JKS & XERS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | JKS | XERS |
|---|---|---|
| Founded | 2006 | 2005 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 1.2B |
| IPO Year | 2010 | 2021 |
Fundamental Metrics
Financial Performance| Metric | JKS | XERS |
|---|---|---|
| Price | $16.96 | $7.48 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 5 | 6 |
| Target Price | ★ $24.80 | $10.83 |
| AVG Volume (30 Days) | 760.9K | ★ 1.6M |
| Earning Date | 04-29-2026 | 05-07-2026 |
| Dividend Yield | ★ 6.04% | N/A |
| EPS Growth | N/A | ★ 100.00 |
| EPS | N/A | ★ 0.01 |
| Revenue | N/A | ★ $49,590,000.00 |
| Revenue This Year | N/A | $34.37 |
| Revenue Next Year | $14.60 | $22.86 |
| P/E Ratio | ★ N/A | $740.00 |
| Revenue Growth | N/A | ★ 142.67 |
| 52 Week Low | $17.15 | $4.52 |
| 52 Week High | $31.88 | $10.08 |
Technical Indicators
Market Signals| Indicator | JKS | XERS |
|---|---|---|
| Relative Strength Index (RSI) | 31.33 | 74.22 |
| Support Level | N/A | $7.27 |
| Resistance Level | $26.41 | $8.43 |
| Average True Range (ATR) | 1.07 | 0.26 |
| MACD | -0.20 | 0.09 |
| Stochastic Oscillator | 3.03 | 91.40 |
Price Performance
Historical ComparisonAbout JKS JinkoSolar Holding Company Limited (each representing 4)
JinkoSolar Holding Co Ltd is engaged in the photovoltaic industry. The firm has built a vertically integrated solar power product value chain, manufacturing from silicon wafers to solar modules. It sells solar modules under the JinkoSolar brand. The company's products include Silicon wafers, Solar cells, and Solar modules. Its geographical segments are China (including Hong Kong and Taiwan), the Americas, Europe, Asia Pacific, and the Rest of the world.
About XERS Xeris Biopharma Holdings Inc.
Xeris Biopharma Holdings Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offers Recorlev for the treatment of endogenous hypercortisolemia in patients with Cushing's syndrome; Gvoke for the treatment of severe hypoglycemia; and Keveyis for the treatment of Primary Periodic Paralysis (PPP). Additionally, the company is advancing its Phase 3-ready pipeline product, XP-8121, a once-weekly subcutaneous injection of levothyroxine, which leverages its proprietary technology, XeriSol.